Dy comparing efficacy and safety of dabigatran etexilate to standard of
Dy comparing efficacy and safety of dabigatran etexilate to IL-4 Protein medchemexpress regular of care in pediatric individuals with venous thromboembolism (VTE) children 18 y old with history of VTE and at least 1 risk aspect for continuation of anticoagulation therapy Age and weight suitable dabigatran twice/ d dosing None Recurrence of VTE at six and 12 mo, significant and minor bleeding Youngsters six mo to 6 y old who have been treated for at least two mo with LMWH and/or VKA for VTE Age and weight acceptable rivaroxaban after every day dosing None Neonates and infants six mo who’ve been treated for at the very least five d with heparin and/or VKA for arterial or venous thrombosis Weight-adjusted rivaroxaban oral suspension (0.1 ) for 7d None Children aged 6 mo to 18 y old with confirmed VTE who obtain initial remedy with heparin and call for anticoagulation for no less than 90 d Youngsters 2 mo to 12 y old with prior VTE Rivaroxaban granules for oral suspension None Age- and weightappropriate rivaroxaban as soon as per day dosing LMWH or VKA Incidence of key bleeding and clinically relevant nonmajor bleeding Plasma concentration of rivaroxaban, anti-Xa activity NCT02197416 SeptemberOpen-label, randomized, parallel-group clinical trialChildren 18 y old with VTE Age and weight proper dabigatran twice/d dosing VKA or LMWH Combined: complete thrombus resolution, recurrent VTE, and mortality associated with VTE NCT01895777 SeptemberJuneAronis and HylekSafety of dabigatran etexilate in blood clot prevention in childrenOpen-label, single-arm potential cohort studyNovemberEINSTEIN Junior Phase II: oral rivaroxaban in young children with venous thrombosisOpen-label, single-arm studyNCTJanuaryApril 2017 (results RANTES/CCL5 Protein Source pending)Rivaroxaban for therapy in venous or arterial thrombosis in neonatesOpen-label, single-arm studyNCTNovemberDecemberEINSTEIN Junior Phase III: oral rivaroxaban in young children with venous thrombosisMulticenter, open-label, active-controlled, randomized clinical trialSymptomatic recurrent venous thromboembolism, key and clinically relevant nonmajor bleeding Region beneath the curve and maximum observed drug concentrationNCTNovemberJulyPhase I study on rivaroxaban granules for oral suspension formulation in kids Neonates to 18 y old and any stable illness which can be at threat for venous or arterial thrombusOpen-label, single-arm pharmacokinetics studyNCTNovemberDecemberJournal on the American Heart AssociationStudy to evaluate a single dose of apixaban in pediatric subjects at danger for a thrombotic disorderOpen-label, single-arm studyApixaban solutionNoneArea below the curve, maximum observed drug concentration, and estimated time at which maximum plasma concentration occursNCTJanuaryOctoberContinuedEvidence Gaps of NOACsCONTEMPORARY REVIEWDOI: ten.1161/JAHA.117.Clinical Trial Patient Population Intervention Comparison Principal Outcome Registration Study Start Date Estimated Completion DateTable 3. ContinuedTrialDesignAronis and HylekA study in the security and effectiveness of apixaban in preventing blood clots in children with leukemia who have a central venous catheter and are treated with pegylated (PEG) L-asparaginase Kids 1218 y old who present with VTE and requiring anticoagulation for 12 wks Youngsters 18 y old who continue to call for anticoagulation therapy and will abstain from the use of nonsteroidal antiinflammatory medications Age and weight acceptable edoxaban when per day dosing None Kids 18 y old with VTE requiring anticoagulation for 90 d that have received a minimum of 5.
